Skip to main content
. 2020 Mar;8(5):237. doi: 10.21037/atm.2019.12.154

Figure 1.

Figure 1

Comparison of OS, DFS between different groups and diagnostic ability for recurrence of various clinical indices. (A) Mean OS between ctDNA positive and negative patients was 22.5 vs. 40.0 months, P<0.001; (B) mean DFS between ctDNA positive and negative patients was 16.6 vs. 35.3 months, P<0.001; (C) mean OS between patients with increased and decreased MAF was 16.8 vs. 25.3 months, P=0.0045; (D) mean DFS between patients with increased and decreased MAF was 7.0 vs. 20.8 months, P<0.001; (E) preoperative ctDNA status ranked the second place in predicting postoperative recurrence among all the parameters assessed with an AUC of 0.625; (F) MAF possessed the greatest AUC (0.710) in predicting postoperative recurrence. OS, overall survival; DFS, disease free survival; ctDNA, circulating tumor DNA; AUC, area under the curve; MAF, mutant allele frequency.